The Top 3 Reasons Psilocybin Mushroom Story is Boo
Post# of 254
(Total Views: 291)
Posted On: 02/19/2020 8:04:00 AM
The Top 3 Reasons Psilocybin Mushroom Story is Booming
Tue February 18, 2020
Houston, Texas--(Newsfile Corp. - February 18, 2020) - MarijuanaStox announces publication of an article that discusses The Yield Growth Corporation (CSE: BOSS) (OTCQB: BOSS). The company has been aggressively addressing demand for health, wellness, and beauty products infused with premium-cannabis and hemp-based products internationally with subsidiary, Urban Juve in addition to psilocybin mushrooms.
Psilocybin Mushroom Boom is Just Getting Underway
The mushroom boom is becoming even more exciting than cannabis.
All thanks to three critical factors.
One, legalization efforts are already well underway.
Denver, Oakland, and Santa Cruz just decriminalized the possession of products containing psilocybin or psilocin. Washington, D.C. could be next. Major institutions are even studying its use for the treatment of depression, addiction, and psychological disorders.
Two, we're seeing a groundswell of scientific evidence that mushrooms are beneficial.
For example, a Johns Hopkins' study also found that 80% of smokers quit after "one dose of psilocybin and research on 51 cancer patients showed the drug decreased anxiety and depression in 80% of those tested," as reported by The Baltimore Sun. Reportedly, Johns Hopkins is also recruiting for studies that use psilocybin for those with early stage Alzheimer's, anorexia-nervosa, and major depression issues.
It's even been found to reduce obsessive compulsive disorder (OCD), anxiety, and depression because it "appears to disrupt the sorts of engrained brain activity patterns that are the hallmark of those diseases," says Business Insider. Other studies are looking at psilocybin mushroom's effect on PTSD, and alcoholism.
Researchers at New York University found psilocybin mushrooms caused a "rapid and sustained" reduction in anxiety and depression in patients with cancer, as reported by the Financial Post, for example. Better, mushrooms are just beginning to disrupt the $4.7 trillion global wellness industry, as its medicinal benefits become better known.
Three, mainstream media has picked up on the story.
It's become so popular Netflix's The Goop Lab, starring Gwyneth Paltrow do an entire episode on the psychedelic drug and its potential benefits.
Yield Growth Corporation is a Major Beneficiary
Yield Growth has made substantial moves into mushrooms.
Just recently, its subsidiary, Flourish Mushroom Labs Inc. signed an agreement with Kingdom Brands Management Inc. Kingdom now has the right to use and sub-license Yield Growth's proprietary extraction technology for use exclusively with both medicinal and psychedelic mushrooms and to further develop the technology.
Flourish Mushroom Labs Inc. also entered into a binding letter of intent with Acres Agricultural Canada Corp. to jointly form a company in Saint Vincent and the Grenadines, Acres Flourish Labs (SVG) Ltd. to build a laboratory for the cultivation of psilocybin mushrooms and for research and development into compounds and therapeutic use of psychedelic mushrooms.
"We are very excited to be the first publicly traded company to announce a legal path to cultivate and research psychedelic mushrooms," says Yield Growth and Flourish CEO Penny White. "There is a renaissance of psychedelic medicine for which investor interest could go viral at any time. We are planning to enter this space with first mover advantage to deliver value to our shareholders."
Flourish also completed the acquisition of a catalogue of mushroom formulas as the foundation of a mushroom edibles business. The formulas and know-how acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer's choice.
The formulations include soups, teas, hot cocoa, elixirs and truffles. Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas, going to market first with mushroom based soups and coffees.
"Our research indicates that edible mushrooms are in a period of high growth," says Yield Growth CEO Penny White. "Yield Growth intends to add to its cannabis wellness assets through acquisitions in companies. Edible Mushrooms may experience hyper-growth as the movement to decriminalize psilocybin (magic mushrooms) grows, similar to how the popularity of hemp has grown with the legalization of cannabis."
For more information, visit the company's website at https://yieldgrowth.com.
https://seekingalpha.com/pr/17782096-top-3-re...is-booming
Tue February 18, 2020
Houston, Texas--(Newsfile Corp. - February 18, 2020) - MarijuanaStox announces publication of an article that discusses The Yield Growth Corporation (CSE: BOSS) (OTCQB: BOSS). The company has been aggressively addressing demand for health, wellness, and beauty products infused with premium-cannabis and hemp-based products internationally with subsidiary, Urban Juve in addition to psilocybin mushrooms.
Psilocybin Mushroom Boom is Just Getting Underway
The mushroom boom is becoming even more exciting than cannabis.
All thanks to three critical factors.
One, legalization efforts are already well underway.
Denver, Oakland, and Santa Cruz just decriminalized the possession of products containing psilocybin or psilocin. Washington, D.C. could be next. Major institutions are even studying its use for the treatment of depression, addiction, and psychological disorders.
Two, we're seeing a groundswell of scientific evidence that mushrooms are beneficial.
For example, a Johns Hopkins' study also found that 80% of smokers quit after "one dose of psilocybin and research on 51 cancer patients showed the drug decreased anxiety and depression in 80% of those tested," as reported by The Baltimore Sun. Reportedly, Johns Hopkins is also recruiting for studies that use psilocybin for those with early stage Alzheimer's, anorexia-nervosa, and major depression issues.
It's even been found to reduce obsessive compulsive disorder (OCD), anxiety, and depression because it "appears to disrupt the sorts of engrained brain activity patterns that are the hallmark of those diseases," says Business Insider. Other studies are looking at psilocybin mushroom's effect on PTSD, and alcoholism.
Researchers at New York University found psilocybin mushrooms caused a "rapid and sustained" reduction in anxiety and depression in patients with cancer, as reported by the Financial Post, for example. Better, mushrooms are just beginning to disrupt the $4.7 trillion global wellness industry, as its medicinal benefits become better known.
Three, mainstream media has picked up on the story.
It's become so popular Netflix's The Goop Lab, starring Gwyneth Paltrow do an entire episode on the psychedelic drug and its potential benefits.
Yield Growth Corporation is a Major Beneficiary
Yield Growth has made substantial moves into mushrooms.
Just recently, its subsidiary, Flourish Mushroom Labs Inc. signed an agreement with Kingdom Brands Management Inc. Kingdom now has the right to use and sub-license Yield Growth's proprietary extraction technology for use exclusively with both medicinal and psychedelic mushrooms and to further develop the technology.
Flourish Mushroom Labs Inc. also entered into a binding letter of intent with Acres Agricultural Canada Corp. to jointly form a company in Saint Vincent and the Grenadines, Acres Flourish Labs (SVG) Ltd. to build a laboratory for the cultivation of psilocybin mushrooms and for research and development into compounds and therapeutic use of psychedelic mushrooms.
"We are very excited to be the first publicly traded company to announce a legal path to cultivate and research psychedelic mushrooms," says Yield Growth and Flourish CEO Penny White. "There is a renaissance of psychedelic medicine for which investor interest could go viral at any time. We are planning to enter this space with first mover advantage to deliver value to our shareholders."
Flourish also completed the acquisition of a catalogue of mushroom formulas as the foundation of a mushroom edibles business. The formulas and know-how acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer's choice.
The formulations include soups, teas, hot cocoa, elixirs and truffles. Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas, going to market first with mushroom based soups and coffees.
"Our research indicates that edible mushrooms are in a period of high growth," says Yield Growth CEO Penny White. "Yield Growth intends to add to its cannabis wellness assets through acquisitions in companies. Edible Mushrooms may experience hyper-growth as the movement to decriminalize psilocybin (magic mushrooms) grows, similar to how the popularity of hemp has grown with the legalization of cannabis."
For more information, visit the company's website at https://yieldgrowth.com.
https://seekingalpha.com/pr/17782096-top-3-re...is-booming
(0)
(0)Better Plant Sciences Inc. (VEGGD) Stock Research Links
Scroll down for more posts ▼